摘要
目的分析顺铂或卡培他滨联合吉西他滨治疗晚期转移性乳腺癌的疗效和安全性。方法将80例晚期转移性乳腺癌患者随机分为A组和B组,每组各40例。A组采用吉西他滨联合顺铂治疗,B组采用吉西他滨联合卡培他滨治疗。观察和比较两组患者的治疗有效率和毒副反应。结果 A组患者的缓解率为27.5%,B组患者的缓解率为50.0%,两组间差异有统计学意义(P<0.05);两组间骨髓抑制的发生率和严重程度无明显差异(P>0.05),但B组的消化道和血液系统毒副反应均较A组轻,差异有统计学意义(P<0.05)。结论吉西他滨联合卡培他滨治疗晚期转移性乳腺癌患者的治疗效果和安全性均优于吉西他滨联合顺铂,值得临床进一步推广应用。
Objective To analyze the efficacy and safety of capecitabine or cisplatin in combination with gemcitabine for patients with advanced metastatic breast cancer. Methods A total of 80 patients with advanced metastatic breast cancer patients were randomly divided into group A and group B, 40 patients in each group. Group A adopted the therapy of gemcitabine plus cisplatin, and group B adopted the therapy of gemcitabine plus capecitabine. Observed and compared the treatment effectiveness and toxicity between the two groups of patients. Results Group A had a remission rate of 27.5%, but group B had a remission rate of 50.0%. The difference in remission rate was statistically significant between the two groups（P〈0.05）. As for the chemotherapy toxicity, the two groups showed no significant differences in the incidence and severity of myelosuppression. However, patients in group A had significantly worse toxic reactions in digestive and hematic system than group B patients, and difference had statistical significance（P〈0.05）. Conclusion Gemcitabine plus capecitabine therapy had superior efficacy and safety to gemcitabine plus cisplatin therapy for patients with advanced metastatic breast cancer, and is worthy of further clinical application.
出处
《肿瘤药学》
CAS
2015年第4期301-304,共4页
Anti-Tumor Pharmacy
关键词
吉西他滨
联合用药
转移性乳腺癌
Gemcitabine
Combination therapy
Metastatic breast cancer
作者简介
刘洪，男，主治医师，研究方向：肿瘤内科化疗，E—mail：liuhong9911@126．com。
